Targeted therapies have gained importance in the field, and the tumor protein p53 is considered a relevant therapeutic target in CRC [7,8], continuing to figure as the most inactivated protein in spontaneous human cancers [9,10]. The gene discussed is TP53; the disease is colorectal carcinoma.